Business context and reporting period
Filing identity: The supplied filing is Catalyst Biosciences, Inc.’s Form 10-Q for the quarter ended June 30, 2020—not a filing identified as Gyre Therapeutics, Inc. The company is a clinical-stage biopharmaceutical business developing protease-based candidates for bleeding and complement-mediated disorders. Figures below are in U.S. dollars; financial statement amounts are in millions unless noted.
Financial performance and position
| Metric | Q2 2020 | Q2 2019 | Six months 2020 | Six months 2019 |
|---|---|---|---|---|
| License and collaboration revenue | $1.66 | $0 | $18.02 | $0 |
| Operating expenses | $19.02 | $14.38 | $40.45 | $30.09 |
| Operating loss | $(17.36) | $(14.38) | $(22.43) | $(30.09) |
| Net loss | $(17.25) | $(13.78) | $(21.30) | $(28.86) |
| Net loss per share | $(0.96) | $(1.15) | $(1.31) | $(2.41) |
- Q2 revenue was collaboration revenue and a small amount of license revenue. First-half license revenue included the $15.0 million Biogen upfront payment; reported revenue is not product sales.
- Revenue less license and collaboration costs was approximately a $0.08 million deficit in Q2 and $11.80 million for the first half, reflecting the upfront license revenue and related costs. The filing does not present a standard gross-margin subtotal.
- Research and development expense rose 16% in Q2 and 13% in the first half year over year; general and administrative expense rose 34% and 16%, respectively.
- At June 30, cash and cash equivalents were $59.3 million and short-term investments were $58.1 million, totaling $117.4 million. Current assets were $121.3 million versus current liabilities of $13.7 million. Total liabilities were $14.7 million, including operating lease liabilities; the filing reports no borrowings.
- First-half operating cash use was $19.9 million, investing cash provided was $3.4 million, and financing cash provided was $60.5 million. Financing included approximately $60.0 million net proceeds from February and June stock offerings.
Material changes versus prior comparable periods
Q2 net loss widened by $3.5 million year over year as operating expenses increased and interest income declined. First-half net loss narrowed by $7.6 million, primarily because of the Biogen revenue, despite higher operating expenses. The company issued 9.9 million shares in its two 2020 offerings; common shares outstanding increased from 12.0 million at year-end 2019 to 22.1 million at June 30, 2020.
Outlook, commentary, risks and unusual items
- Management expected available cash, cash equivalents and investments to fund requirements for at least 12 months from the filing date, while anticipating continued losses and significant expenses for several years. Future financing may be needed; availability and terms are uncertain.
- Management expected to enroll the first patient in a MarzAA Phase 3 trial in late 2020 and described a separate MarzAA Phase 1/2 study as planned for late 2020. DalcA Phase 2b results included protective FIX levels in participants, with one withdrawal following injection-site reactions; these are company-reported clinical findings, not regulatory approval.
- Biogen may terminate its agreement on 60 days’ notice. The company is eligible for up to $340 million in development and sales milestones plus royalties, but timing and receipt are uncertain. The May Mosaic amendment involved a $0.8 million payment and up to $4.0 million in potential future milestones.
- COVID-19 could delay or disrupt trial enrollment, clinical sites, data analysis, research, manufacturing and supply logistics, potentially increasing costs. The company reported $3.2 million remaining on AGC manufacturing work orders at quarter-end.
- Subsequent to quarter-end, the company agreed to pay up to approximately $7.2 million for a MarzAA Phase 1/2 study work order and up to approximately $14.0 million for a MarzAA Phase 3 study task order.
- The company reported no material legal proceedings and no off-balance-sheet arrangements. It stated disclosure controls were effective as of June 30, 2020.
Important facts for investors to verify
- Confirm the intended issuer: the provided filing names Catalyst Biosciences, Inc., while the request metadata names Gyre Therapeutics, Inc.
- Verify cash runway assumptions against planned clinical, manufacturing and research spending, including the post-quarter study commitments.
- Assess whether clinical timelines and trial execution are affected by COVID-19, and track actual enrollment and results against management’s expectations.
- Review Biogen agreement economics, termination rights, milestone conditions and the timing and recognition of collaboration reimbursements.
- Consider the dilution from the 2020 offerings and the company’s continuing dependence on external financing while it remains unprofitable.